

September 3, 2025

Company Update

☑ Change in Estimates | ■ Target | ■ Reco

Change in Estimates

	Current		Previous	
	FY26E	FY27E	FY26E	FY27E
Rating	BUY		BUY	
Target Price	9,300		9,300	
Sales (Rs.m)	2,49,203	2,93,507	2,49,085	2,94,536
% Chng.	-	(0.3)		
EBITDA (Rs.m)	38,048	48,639	38,194	48,760
% Chng.	(0.4)	(0.2)		
EPS (Rs.)	134.6	184.7	135.3	185.3
% Chng.	(0.5)	(0.3)		

Key Financials - Consolidated

Y/e Mar	FY25	FY26E	FY27E	FY28E
Sales (Rs. m)	2,17,940	2,49,203	2,93,507	3,39,342
EBITDA (Rs. m)	30,218	38,048	48,639	60,147
Margin (%)	13.9	15.3	16.6	17.7
PAT (Rs. m)	14,459	19,357	26,562	34,799
EPS (Rs.)	100.5	134.6	184.7	242.0
Gr. (%)	60.9	33.9	37.2	31.0
DPS (Rs.)	11.4	14.8	17.1	20.5
Yield (%)	0.1	0.2	0.2	0.3
RoE (%)	19.1	21.4	23.9	25.1
RoCE (%)	19.2	21.3	25.5	28.2
EV/Sales (x)	5.2	4.5	3.8	3.3
EV/EBITDA (x)	37.3	29.5	23.0	18.3
PE (x)	76.3	57.0	41.5	31.7
P/BV (x)	13.4	11.1	9.0	7.2

Key Data

APLH.BO | APHS IN

52-W High / Low	Rs.7,981 / Rs.6,001
Sensex / Nifty	80,158 / 24,580
Market Cap	Rs.1,103bn / \$ 12,514m
Shares Outstanding	144m
3M Avg. Daily Value	Rs.3757.21m

Shareholding Pattern (%)

Promoter's	29.34
Foreign	43.49
Domestic Institution	21.57
Public & Others	5.60
Promoter Pledge (Rs bn)	42.43

Stock Performance (%)

	1M	6M	12M
Absolute	4.4	26.8	11.5
Relative	4.9	15.8	14.9

Param Desai

paramdesai@plindia.com | 91-22-66322259

Sanketa Kohale

sanketakhale@plindia.com | 91-22-66322426

Strong case for re-rating

Apollo hospitals enterprise's (APHS IN) stock has underperformed since FY24 versus its peers (MAXHEALT, KIMS, FORH). We believe underperformance was due to relatively moderate growth in the Hospitals segment, elevated losses from Apollo 24x7 business and stake sale of Apollo HealthCo (AHL) to Advent in Apr'24 at below market expectations. As part of the ongoing process, these concerns are addressed via 3,577 bed additions over the next 3-4 years, reducing losses in 24x7 and likely breakeven by H1CY26, and listing of HealthCo by FY27 end to unlock value.

Overall, we estimate 26% EBITDA CAGR over FY25-28E. At CMP, APHS is trading at 22x EV/EBITDA on Sept 2027E adjusted for minority and rental. Ascribing 27x EV/EBITDA to HealthCo, APHS Hospitals + Diagnostics business is available at ~20x EV/EBITDA on Sept 2027E, which is at 15-30% discount to peers. We ascribe 27x EV/EBITDA multiple to Hospitals and HealthCo based on Sept 2027E. We recommend 'BUY' rating with TP of Rs9,300/share.

New bed additions to drive next phase of growth: APHS delivered a healthy 14% EBITDA CAGR over FY22-25, despite negligible capacity additions (150 beds). The company is set to operationalize 7 new hospitals (1,577 census beds) across key metros such as Delhi, Pune, Kolkata and Bengaluru over the next 12 months. Overall, 3,577 census beds, ~40% of existing census beds, are likely to be operationalized over the next 3-4 years. Given majority of these additions are greenfield, benefits will be visible from H2FY27/FY28. Initially, the management guided Rs1.5bn cumulative losses from new units over 2 years, with potential breakeven within 12 months of commercialization. We have factored in 16% EBITDA CAGR from the Hospitals segment over FY25-28E.

Breakeven in Apollo 24x7 by H1CY26: Apollo HealthCo's scale-up remains on track with losses on a declining trend. Cash losses reduced sharply from Rs1.75bn in Q1FY24 to Rs963mn in Q1FY26, driven by improved unit-level economics, renegotiation of vendor contracts, and better insurance monetization. The management has guided for breakeven in EBITDA of digital business over the next 3-4 quarters. Further, the merger with Keimed will be positive as the company intends to leverage Keimed's vast network and accelerate its private label portfolio.


Demerger of Apollo HealthCo to unlock value: Demerger of HealthCo will allow shareholders to participate in each entity separately, enabling full discovery value and eliminating any HoldCo discount. HealthCo will have retail pharmacy business (SAP), 24x7 online platform and pharmacy distribution business (Keimed). HealthCo is expected to be listed by Q4FY27 end. Post Keimed merger, APHS will have 59.6% stake in HealthCo. During FY25, HealthCo reported Pre Ind As EBITDA of Rs6.4bn, which included Rs4.8bn of losses from 24x7. The management has guided HealthCo to achieve Rs17.5bn EBITDA by FY27.

EBITDA to grow 2x over FY25-28E: We see strong potential for EBITDA growth of 26% CAGR over FY25-28E, led by clear visibility on hospital expansion, impending breakeven in Apollo 24x7, and healthy growth of 25%+ across SAP and Diagnostics businesses. Faster ramp-up of new units in Hospitals segment and timely breakeven of the 24x7 segment will be key to achieving this EBITDA growth.

Hospitals business - new bed addition to drive next phase of growth


- APHS is among Asia's largest healthcare providers in India, with ~8,754 bed capacity (8,030 operational) across 45 owned hospitals. Its focus on superior clinical outcomes has established it as a leading brand in India's healthcare industry.
- Despite limited bed additions in bed capacity, the Hospitals business has delivered 14% EBITDA CAGR with margin expansion of ~110bps over FY22-25. Hospitals OPM reached 24.2% in FY25, driven by optimized capacity utilization across mature hospitals and ramp-up at newer facilities, supporting operating leverage.
- EBITDA growth was also driven by higher contributions from tertiary/quaternary care, complex procedures, and international patients, which led to better ARPOB.
- Hospitals business generated ARPOB of Rs60.6k per day in FY25 (clocked 10% CAGR over FY22-25), led by annual price revisions, lower ALOS, and better case and payer mix (self-payers + insurance contribution at 85%). We expect ARPOB to deliver annual growth of 6-7% in the next 2-3 years.

Exhibit 1: ARPOB growth driven by ALOS reduction, better case and payor mix




Source: Company, PL

Exhibit 2: 56% contribution from Cardio, Onco, Neuro & Ortho



Source: Company, PL


Exhibit 3: 85% contribution of cash + insurance business



Source: Company, PL


- APHS's occupancies improved to 68% in FY25 (from 63% in FY22) on improved occupancies and lower ALOS, aided by operating leverage without adding fixed cost. We expect occupancies to remain steady for FY26 as 1,577 census beds capacity will be added, and to improve gradually thereafter as new hospitals ramp up.

Exhibit 4: Occupancies improve by 500bps over FY22-25



Source: Company, PL

Exhibit 5: Lower ALOS resulted in better efficiency



Source: Company, PL

Exhibit 6: APHS plans to add 3,577 census beds over next 3-4 years


Project	Type	Total beds	Census beds	Project cost (Rs mn)
Expected commissioning: FY26				
Royal Mudhol, Pune	Hospital asset acquisition	400	325	6300
Sonarpur Kolkata	Hospital asset acquisition	270	220	3100
Gachibowli, Hyderabad	Greenfield - Asset light	375	300	5150
Gurugram	Hospital asset acquisition	510	420	11,900
Malleswaram & Mysore expansion	Brownfield	140	125	1700
Defence Colony, Delhi	Brownfield	42	27	650
Sarjapur 1	Acquisition - Lease facility	200	160	2850
		1,937	1,577	31,650
Expected commissioning: In next 3-4 years				
OMR, Chennai	Greenfield	600	500	9450
Varanasi, UP	Greenfield	400	300	6400
Worli, Mumbai	Greenfield	575	500	13150
Lucknow (Phase 2), UP	Brownfield	200	160	3200
Sarjapur Phase 2	Greenfield	500	400	9440
Jubilee Hills (expansion)	Brownfield	80	70	2200
Secunderabad (expansion)	Brownfield	80	70	540
		2,435	2,000	44,380
Total		4,372	3,577	76,030

Source: Company, PL

- FY26 bed expansion: The company is on track to commission 1,577 census beds in FY26E, with 720 in Gurugram and Hyderabad, and remaining to be added across key metros such as Delhi, Pune, Kolkata, and Bengaluru over the next 12 months.

- For the medium term, APHS targets the addition of 3,577 census beds over the next 3–4 years with a capex outlay of Rs76bn, of which Rs54bn is yet to be deployed. which should accelerate Hospitals growth further once the newer units start ramping up.
- The management has guided increase of the EBITDA margin of existing network hospitals to 25% (currently at 24.2%) before factoring in new hospitals' losses. New hospitals are expected to incur cumulative EBITDA loss of Rs1.5bn over the next 2 years, with potential breakeven in 12 months of commercialization and ramp-up thereafter.
- We expect international patients' contribution to further increase with potential recovery in footfalls from Bangladesh. The management is keen on exploring Iraq as a new growth market and expects international patients to contribute to 7% and 10% of Hospitals revenue by the end of FY26E and FY27E, respectively.
- We expect consol Hospitals EBITDA to increase at 16% CAGR over FY25-28E to Rs42bn.

Exhibit 7: Margins to remain steady despite bed additions




Source: Company, PL

Breakeven in Apollo 24x7 to support growth

- APHS's digital platform, Apollo 24x7 has created the largest omni-channel healthcare ecosystem in India with 41mn+ registered users and ~0.8mn daily active users. The scale ensures lower customer acquisition costs and recurring engagement, driving stronger unit economics. The network of 6,742 pharmacies provides a deep distribution moat, making Apollo the only player capable of offering seamless online-to-offline experience in healthcare.
- Platform GMV figures for past periods have been restated based on the new definition. This year onwards, new customer business will only be considered for GMV.
- Platform GMV stood at Rs 6.8bn in Q1FY26, up 23% YoY. Management indicated that a quarterly GMV run rate of Rs 8bn would be sufficient to achieve breakeven. For FY26, the company has guided to a GMV target of Rs 32bn, with a GMV-to-revenue conversion ratio of 45–46%. Incremental growth is expected to be supported by insurance partnerships, ramping up app monetization initiatives, and expanding corporate tie-ups.
- Apollo 24x7's losses have started declining, with cash losses halving over the past 2 years. Cash losses narrowed from Rs1.75bn in Q1FY24 to Rs963mn in Q1FY26, due to improved unit economics, renegotiated vendor rates, and insurance monetization (~Rs50mn in Q1).
- The management targets the digital business to break even by FY26-end along with long-term growth expectation at 20–25% annually.

Exhibit 8: Cash losses reduce sharply to Rs963mn in Q1FY26




Source: Company, PL

Demerger of Apollo HealthCo to unlock value


- This strategic step will allow shareholders to participate directly in a focused, consumer-centric, high-growth platform, while APHS sharpens its focus on core hospital operations. The move eliminates HoldCo discount and ensures full value discovery of both businesses.
- The proposed merger of Keimed with HealthCo will lead to the creation of India's leading integrated pharmacy distribution and digital health business. Keimed's vast network of 75k+ pharmacies and 101 distribution centers will be leveraged to improve service levels, strengthen supply chain efficiencies, and accelerate growth in Apollo's private label portfolio, leading to margin expansion.
- APHS shareholders will receive 195.2 shares of NewCo for every 100 shares, translating to ~667mn outstanding shares post-transaction (incl. ESOP pool). Post-merger, APHS will hold 59.6% stake; Advent International, ~12%; Keimed, 25.7%; and ESOPs, ~3%.
- The combined entity will consolidate Apollo Pharmacy Ltd by acquiring the remaining 74.5% stake in Apollo Medicals for capital outlay of Rs3bn.
- Listing of NewCo is expected in Q4FY27–Q1FY28 post regulatory approvals. NewCo will be listed as an Indian-owned controlled company, and APHS will retain a strategic 17.5% stake, with aligned interests safeguarded through a collaborative business framework agreement.
- The management has guided NewCo to achieve ~Rs250bn revenue by FY27, implying 22–23% CAGR, with EBITDA margin expanding to ~7% (from ~3.5% in FY25). Margin levers include breakeven of Apollo 24x7 in the next 3-4 quarters, higher private label contribution (10–12% by FY27), monetization of digital assets (ads, insurance, branded generics), and synergies with Keimed's supply chain.

Exhibit 9: Offline pharmacy revenue to grow at 15% CAGR




Source: Company, PL

Exhibit 10: Offline pharmacy EBITDA to grow at ~21% CAGR




Source: Company, PL

Exhibit 11: 24x7 revenues to grow at ~22% CAGR




Source: Company, PL

Exhibit 12: Expect breakeven by end of FY26E




Source: Company, PL Note: Ex of ESOPs

Exhibit 13: Keimed EBITDA to grow at 15% CAGR



Source: Company, PL

Exhibit 14: HealthCo EBITDA to grow at 48% CAGR




Source: Company, PL

- The management has reiterated EBITDA guidance of Rs17.5bn by FY27 for the merged entity; it stood at Rs6.4bn as of FY25. With FY25 offline pharmacy EBITDA margins at 9.4% and Keimed at ~3.2%, scaling margins to 7–8% appears achievable with higher private labels and cost synergies.
- The Rs24.75bn (\$300mn) capital infusion by Advent provides growth visibility for the next 5 years. The combined entity's net worth stood at ~Rs34bn in FY25 with manageable net debt of ~Rs19.3bn. Advent's long-term investment horizon, coupled with a potential IPO or exit in 7 years, ensures disciplined capital allocation and governance.
- A business framework agreement ensures non-compete and alignment of interests. NewCo will pay brand royalty to APHS (~Rs100mn p.a. initially) while continuing to act as the exclusive partner for Apollo-branded pharmacy and digital services. This ensures value-accretive collaboration without overlaps.
- **We value HealthCo at Rs510bn (based on Rs18bn EBITDA by Sept2027E at 27x EV/EBITDA). APHS will hold 59.6% stake in HealthCo post Keimed merger, which translates into Rs304bn.**

Valuation and outlook:

- APHS has underperformed peers (MAXHEALT, KIMS, FORH) since FY24, largely on account of moderate growth in the Hospitals segment and elevated losses in the digital business.

Exhibit 15: APHS underperformed compared to its peers



Source: Company, PL

- We see strong potential for EBITDA growth of 26% CAGR over FY25-28E, with clear visibility on hospital expansion, impending breakeven in Apollo 24x7, and value unlocking through the demerger.
- With strong brand equity, large-scale expansion, integrated digital + offline presence, and improving unit economics, APHS remains structurally best placed in the sector. Near-term catalysts include timely commissioning of new hospitals, breakeven in Apollo 24x7, and clarity on the NewCo listing, all of which could drive earnings upgrades and stock re-rating.
- We recommend 'BUY' with TP of Rs9,300/share, ascribing 27x EV/EBITDA to hospitals and HealthCo based on Sept2027E.

Exhibit 16: Peer valuation

Peer hospital companies	MCap (Rs bn)	EV/EBITDA (x)		PE (x)		ROE (x)		ROCE (x)		Pre IND AS EBITDA CAGR (%)
		FY26E	FY27E	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E	FY25-27E
APHS	1101	35.0	26.7	56.9	41.4	21.4	24.0	21.3	25.5	25.4
ASTERDM	312	34.6	26.7	114.7	80.8	14.3	18.3	16.0	21.0	24.0
FORH	702	35.7	29.8	67.5	52.0	10.8	12.5	14.1	16.0	22.1
HCG	93	28.9	23.4	91.6	49.2	9.8	15.9	13.7	17.2	25.7
KIMS	298	39.0	28.0	76.9	51.9	16.0	19.8	15.5	19.5	33.3
MAXHEALT	1133	40.1	32.2	57.0	43.4	17.4	19.5	18.2	20.7	23.9
NARH	370	26.0	21.7	40.1	31.3	22.9	23.9	18.6	20.9	17.5
JLHL	92	24.8	21.0	42.8	36.4	14.7	15.0	15.3	16.0	20.0
RAINBOW	153	30.1	24.7	51.9	39.9	18.4	20.3	22.3	23.6	19.7

Source: PL, (Note: 1) EV/EBITDA is on Pre-IND AS basis, 2) Fortis, HCG, ASTERDM and KIMS EV/ EBITDA is adjusted for minority stake, 3) ASTERDM EV/EBITDA is for combined entity

Exhibit 17: SOTP

Rs bn	Sept 2027 Pre-Ind AS EBITDA	Target EV/EBITDA (x)	EV	APHS stake (%)	APHS stake
Hospitals	37	27	1,002	100	1,002
HealthCo	19		510		
SAP- Offline	12	30	354	59.6	211
24x7	2	30	45	59.6	27
Keimed	6	20	111	59.6	66
AHLL	2	25	48	70	33
Total			2,069		1,339
Less net debt					(4)
Mkt cap					1,342
O/S shares - mn					143.8
Target price- Rs/share					9,300

Source: PL

Financials

Income Statement (Rs m)

Y/e Mar	FY25	FY26E	FY27E	FY28E
Net Revenues	2,17,940	2,49,203	2,93,507	3,39,342
YoY gr. (%)	14.3	14.3	17.8	15.6
Cost of Goods Sold	1,13,100	1,24,601	1,46,754	1,69,671
Gross Profit	1,04,840	1,24,601	1,46,754	1,69,671
Margin (%)	48.1	50.0	50.0	50.0
Employee Cost	27,692	32,400	37,908	44,352
Other Expenses	46,930	54,154	60,207	65,172
EBITDA	30,218	38,048	48,639	60,147
YoY gr. (%)	26.4	25.9	27.8	23.7
Margin (%)	13.9	15.3	16.6	17.7
Depreciation and Amortization	7,575	7,802	8,036	8,277
EBIT	22,643	30,246	40,603	51,870
Margin (%)	10.4	12.1	13.8	15.3
Net Interest	4,585	4,500	4,300	4,000
Other Income	2,003	1,800	2,000	2,200
Profit Before Tax	20,061	27,546	38,303	50,070
Margin (%)	9.2	11.1	13.1	14.8
Total Tax	5,340	7,988	11,491	15,021
Effective tax rate (%)	26.6	29.0	30.0	30.0
Profit after tax	14,721	19,557	26,812	35,049
Minority interest	592	500	550	550
Share Profit from Associate	330	300	300	300
Adjusted PAT	14,459	19,357	26,562	34,799
YoY gr. (%)	60.9	33.9	37.2	31.0
Margin (%)	6.6	7.8	9.0	10.3
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	14,459	19,357	26,562	34,799
YoY gr. (%)	61.2	33.9	37.2	31.0
Margin (%)	6.6	7.8	9.0	10.3
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	14,459	19,357	26,562	34,799
Equity Shares O/s (m)	144	144	144	144
EPS (Rs)	100.5	134.6	184.7	242.0

Source: Company Data, PL Research

Balance Sheet Abstract (Rs m)

Y/e Mar	FY25	FY26E	FY27E	FY28E
Non-Current Assets				
Gross Block	1,29,687	1,46,687	1,66,687	1,86,687
Tangibles	1,29,687	1,46,687	1,66,687	1,86,687
Intangibles	-	-	-	-
Acc: Dep / Amortization	54,791	62,594	70,630	78,907
Tangibles	54,791	62,594	70,630	78,907
Intangibles	-	-	-	-
Net fixed assets	74,896	84,094	96,057	1,07,780
Tangibles	74,896	84,094	96,057	1,07,780
Intangibles	-	-	-	-
Capital Work In Progress	9,210	9,210	9,210	9,210
Goodwill	10,305	10,305	10,305	10,305
Non-Current Investments	10,573	10,573	10,573	10,573
Net Deferred tax assets	(4,449)	(4,449)	(4,449)	(4,449)
Other Non-Current Assets	24,653	24,653	24,653	24,653
Current Assets				
Investments	14,323	14,323	14,323	14,323
Inventories	4,808	6,230	7,338	8,484
Trade receivables	30,161	33,642	39,623	45,811
Cash & Bank Balance	13,602	15,028	18,343	29,332
Other Current Assets	-	-	-	-
Total Assets	2,06,443	2,23,361	2,47,259	2,78,988
Equity				
Equity Share Capital	719	719	719	719
Other Equity	81,404	98,321	1,22,067	1,53,486
Total Networth	82,123	99,040	1,22,786	1,54,205
Non-Current Liabilities				
Long Term borrowings	44,170	41,170	38,170	35,170
Provisions	-	-	-	-
Other non current liabilities	-	-	-	-
Current Liabilities				
ST Debt / Current of LT Debt	8,582	8,582	8,582	8,582
Trade payables	22,405	24,920	29,351	33,934
Other current liabilities	40,308	40,794	39,516	38,242
Total Equity & Liabilities	2,06,443	2,23,361	2,47,259	2,78,988

Source: Company Data, PL Research

Cash Flow (Rs m)

Y/e Mar	FY25	FY26E	FY27E	FY28E
PBT	15,051	27,546	38,303	50,070
Add. Depreciation	7,575	7,802	8,036	8,277
Add. Interest	4,585	4,500	4,300	4,000
Less Financial Other Income	2,003	1,800	2,000	2,200
Add. Other	5,052	(200)	(250)	(250)
Op. profit before WC changes	32,263	39,648	50,389	62,097
Net Changes-WC	(5,769)	(3,293)	(5,467)	(5,708)
Direct tax	(4,860)	(7,988)	(11,491)	(15,021)
Net cash from Op. activities	21,634	28,367	33,431	41,369
Capital expenditures	(16,978)	(17,000)	(20,000)	(20,000)
Interest / Dividend Income	-	-	-	-
Others	(11,918)	-	-	-
Net Cash from Invst. activities	(28,896)	(17,000)	(20,000)	(20,000)
Issue of share cap. / premium	-	-	-	-
Debt changes	21,431	(3,000)	(3,000)	(3,000)
Dividend paid	(2,732)	(2,441)	(2,816)	(3,379)
Interest paid	(4,585)	(4,500)	(4,300)	(4,000)
Others	2,322	-	-	-
Net cash from Fin. activities	16,436	(9,941)	(10,116)	(10,379)
Net change in cash	9,174	1,426	3,315	10,989
Free Cash Flow	4,656	11,367	13,431	21,369

Source: Company Data, PL Research

Quarterly Financials (Rs m)

Y/e Mar	Q2FY25	Q3FY25	Q4FY25	Q1FY26
Net Revenue	55,893	55,269	55,922	58,421
YoY gr. (%)	15.3	13.9	13.1	14.9
Raw Material Expenses	28,577	29,007	29,286	30,476
Gross Profit	27,316	26,262	26,636	27,945
Margin (%)	48.9	47.5	47.6	47.8
EBITDA	8,155	7,615	7,697	8,519
YoY gr. (%)	30.0	24.1	20.2	26.2
Margin (%)	14.6	13.8	13.8	14.6
Depreciation / Depletion	1,845	1,846	2,110	2,147
EBIT	6,310	5,769	5,587	6,372
Margin (%)	11.3	10.4	10.0	10.9
Net Interest	1,175	1,098	1,148	1,083
Other Income	382	638	611	402
Profit before Tax	5,517	5,309	5,050	5,691
Margin (%)	9.9	9.6	9.0	9.7
Total Tax	1,617	1,568	1,010	1,417
Effective tax rate (%)	29.3	29.5	20.0	24.9
Profit after Tax	3,900	3,741	4,040	4,274
Minority interest	169	71	249	82
Share Profit from Associates	57	53	105	136
Adjusted PAT	3,788	3,723	3,896	4,328
YoY gr. (%)	64.0	51.8	53.5	41.8
Margin (%)	6.8	6.7	7.0	7.4
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	3,788	3,723	3,896	4,328
YoY gr. (%)	64.0	51.8	53.5	41.8
Margin (%)	6.8	6.7	7.0	7.4
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	3,788	3,723	3,896	4,328
Avg. Shares O/s (m)	-	-	-	-
EPS (Rs)	26.3	25.9	27.1	30.1

Source: Company Data, PL Research

Key Financial Metrics

Y/e Mar	FY25	FY26E	FY27E	FY28E
Per Share(Rs)				
EPS	100.5	134.6	184.7	242.0
CEPS	153.2	188.9	240.6	299.6
BVPS	571.1	688.7	853.9	1,072.4
FCF	32.4	79.0	93.4	148.6
DPS	11.4	14.8	17.1	20.5
Return Ratio(%)				
RoCE	19.2	21.3	25.5	28.2
ROIC	12.7	15.6	18.9	22.0
RoE	19.1	21.4	23.9	25.1
Balance Sheet				
Net Debt : Equity (x)	0.3	0.2	0.1	-
Net Working Capital (Days)	21	22	22	22
Valuation(x)				
PER	76.3	57.0	41.5	31.7
P/B	13.4	11.1	9.0	7.2
P/CEPS	50.1	40.6	31.9	25.6
EV/EBITDA	37.3	29.5	23.0	18.3
EV/Sales	5.2	4.5	3.8	3.3
Dividend Yield (%)	0.1	0.2	0.2	0.3


Source: Company Data, PL Research

Key Operating Metrics

Y/e Mar	FY25	FY26E	FY27E	FY28E
Pharmacy	90,930	1,06,450	1,23,091	1,42,364
AHLL	15,535	17,710	20,012	22,814
Healthcare services	1,11,475	1,25,043	1,50,404	1,74,164

Source: Company Data, PL Research

Price Chart



Recommendation History

No.	Date	Rating	TP (Rs.)	Share Price (Rs.)
1	14-Aug-25	BUY	9,300	7,809
2	08-Jul-25	BUY	8,350	7,616
3	02-Jul-25	BUY	8,350	7,496
4	01-Jun-25	BUY	8,100	6,881
5	08-Apr-25	BUY	8,100	6,683
6	12-Feb-25	BUY	8,100	6,317
7	08-Jan-25	BUY	8,000	7,437
8	08-Nov-24	BUY	8,000	7,410
9	07-Oct-24	BUY	7,150	6,774

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Apollo Hospitals Enterprise	BUY	9,300	7,809
2	Aster DM Healthcare	BUY	700	605
3	Aurobindo Pharma	BUY	1,300	1,079
4	Cipla	BUY	1,730	1,533
5	Divi's Laboratories	Accumulate	6,550	6,134
6	Dr. Reddy's Laboratories	Reduce	1,270	1,247
7	Eris Lifesciences	BUY	1,975	1,808
8	Fortis Healthcare	BUY	1,000	884
9	HealthCare Global Enterprises	BUY	620	560
10	Indoco Remedies	Hold	325	322
11	Ipca Laboratories	Accumulate	1,525	1,377
12	J.B. Chemicals & Pharmaceuticals	BUY	2,030	1,778
13	Jupiter Life Line Hospitals	BUY	1,720	1,451
14	Krishna Institute of Medical Sciences	BUY	815	745
15	Lupin	BUY	2,400	1,852
16	Max Healthcare Institute	BUY	1,355	1,221
17	Narayana Hrudayalaya	BUY	2,000	1,830
18	Rainbow Children's Medicare	BUY	1,725	1,541
19	Sun Pharmaceutical Industries	BUY	1,875	1,707
20	Sunteck Realty	BUY	650	427
21	Torrent Pharmaceuticals	Accumulate	4,000	3,623
22	Zydus Lifesciences	Accumulate	970	956

PL's Recommendation Nomenclature (Absolute Performance)

Buy	: > 15%
Accumulate	: 5% to 15%
Hold	: +5% to -5%
Reduce	: -5% to -15%
Sell	: < -15%
Not Rated (NR)	: No specific call on the stock
Under Review (UR)	: Rating likely to change shortly

ANALYST CERTIFICATION

(Indian Clients)

We/I, Mr. Param Desai- MBA Finance, Ms. Sanketa Kohale- MBA Finance Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Param Desai- MBA Finance, Ms. Sanketa Kohale- MBA Finance Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

www.plindia.com